Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6147 participants.

Also called NCT02525939

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 6,147 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02525939
Other papers using this trial's data
  • Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial European heart journal, 2022-10-14 DOI, PubMed 35856777, PMC9565632 PubMed links an erratum for this paper. Erratum: PMID 36130114 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Türkiye, United Arab Emirates, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02525939. Randomized; quadruple masking; primary purpose treatment. Start 2016-04 (actual); primary completion 2021-10 (actual). Results posted on 2022-10-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
Acronym
dal-GenE
Condition
Acute Coronary Syndrome
Intervention (Drug)
dalcetrapib
Intervention (Drug)
Placebo
Lead sponsor
DalCor Pharmaceuticals (class: industry)
Collaborator
The Montreal Health Innovations Coordinating Center (MHICC) (class: other)
Collaborator
Medpace, Inc. (class: industry)
Collaborator
Roche Molecular Systems, Inc (class: industry)

Record details

Record id
cardio:ct-nct02525939
Content hash
43990e8b2ef053b4d41784c2b1b33470be7c138ae8908f3e9753311650b84a6f